About Acarix

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care.

The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures.2

The CADScor System has been used on more than 29,000 patients.3 Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care.1

Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, certifiedadviser@penser.se) is the Certified Advisor of Acarix.

Our Mission

Acarix is on a mission to transform early cardiac diagnostics by delivering accessible, easy-to-use acoustic-based solutions that provide accurate and timely results to healthcare professionals and patients at point-of-care

Our Vision

Acarix envisions a future where first-line cardiac diagnostics are accessible, rapidly provide results, and accurate for all patients, regardless of geographic location or socioeconomic status


An advanced acoustic-based diagnostic aid to easily and quickly rule out significant coronary artery disease at point of care.*

Learn more about CADScor®System

Our Offices

Contact Us

Please visit our contact page to get in touch.

Go to contact page
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.
  3. Based on commercial patch use since 2017